Hyperpolarized 13c-Mri, Metabolomics, and Radiomics for Immune Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab

Project: National Science and Technology CouncilNational Science and Technology Council Academic Grants

Project Details

Abstract

在中晚期肝癌患者,放射治療合併癌自禦(抗PD-L1)及癌思停(抗 VEGF)可誘發全身性抗癌免疫反應,降低復發風險,然而目前仍缺乏可靠的影像生物標誌來預測患者對放射免疫治療的反應。本臨床試驗欲結合超極化13C-MRI、代謝體學及放射影像組學,深入研究放射免疫治療在肝癌患者中的免疫反應及代謝影響。透過分析腫瘤及脾臟代謝動態、血清代謝物、循環腫瘤DNA、多參數流式細胞儀免疫分型及細胞激素微陣技術,全面觀察免疫反應與代謝變化,並結合空間轉錄組學技術探討腫瘤微環境,以了解放射免疫治療的作用機轉,而試驗發現將透過同源小鼠模型與患者來源異種移植模型進一步驗證,以提升臨床應用的可轉譯性。本研究將為肝癌個人化治療提供新穎的生物標誌,推動癌症精準醫療的進展。

Project IDs

Project ID:PC11406-0112
External Project ID:NSTC114-2326-B182-001-MY3
StatusActive
Effective start/end date01/08/2531/07/26

Keywords

  • Hyperpolarized 13C-MRI
  • Metabolomics
  • Radioimmunotherapy
  • Tumor Microenvironment
  • Spatial Transcriptomics
  • Circulating Tumor DNA
  • Radiomics
  • Patient-Derived Xenograft
  • Hepatocellular Carcinoma

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.